Inactive Instrument

MDxHealth SA Share Price Euronext Bruxelles

Equities

MDXH

BE0974461940

Biotechnology & Medical Research

Financials

Sales 2023 64.39M 68.84M 5.51B Sales 2024 * 73.53M 78.62M 6.3B Capitalization 63.14M 67.51M 5.41B
Net income 2023 -39M -41.7M -3.34B Net income 2024 * -26M -27.8M -2.23B EV / Sales 2023 1.51 x
Net cash position 2023 * - 0 0 Net cash position 2024 * - 0 0 EV / Sales 2024 * 0.86 x
P/E ratio 2023
-2.37 x
P/E ratio 2024 *
-2.46 x
Employees 255
Yield 2023 *
-
Yield 2024 *
-
Free-Float 97.37%
More Fundamentals * Assessed data
Dynamic Chart
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Calendar
More about the company